21 April 2015 | News | By BioSpectrum Bureau
PPD opens central lab in Shanghai
All of PPD's central labs use identical testing platforms, calibrators and reagents for all laboratory assays
Singapore: Pharmaceutical Product Development (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been established in association with the Shanghai Clinical Research Center (SCRC), is equipped with cutting-edge analytical equipment to provide high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development.
The central lab service offering of PPD includes safety and general lab testing, specialized testing, biomarker testing, and custom assay development and testing services. This new operation provides the same services as PPD's other central labs in Brussels, Belgium; Highland Heights, Kentucky and Singapore. All of PPD's central labs use identical testing platforms, calibrators and reagents for all laboratory assays. In addition, the same lot numbers of standards for calibration are used across all labs, ensuring identical results regardless of where testing is performed.
"Our global network of central labs is committed to bringing value across the product development continuum. We deliver world-class scientific expertise, innovative platforms, flexible service models and operational efficiencies to ensure successful execution across every step of the development process. The standardized, global platforms and Web-based database of our central labs ensure superior service, quality data, and exceptional speed and flexibility for our clients," said Dr Andrew Cunningham, vice president of Global Laboratory Services at PPD.
The Shanghai laboratory leverages PPD's 30 years of global laboratory expertise, broad therapeutic experience, and state-of-the-art facilities and instrumentation in delivering best-in-class laboratory services for its clients.
The new facility is accredited via SCRC's medical license issued by China's Ministry of Health, as well as the College of American Pathologists, NGSP and ISO 15189 certifications-all of which are crucial to conducting clinical trials in China successfully.